ECSP088189A - Derivados de 3-sulfonilindazol sustituido comoligandos de 5-hidroxitriptamina-6 - Google Patents

Derivados de 3-sulfonilindazol sustituido comoligandos de 5-hidroxitriptamina-6

Info

Publication number
ECSP088189A
ECSP088189A EC2008008189A ECSP088189A ECSP088189A EC SP088189 A ECSP088189 A EC SP088189A EC 2008008189 A EC2008008189 A EC 2008008189A EC SP088189 A ECSP088189 A EC SP088189A EC SP088189 A ECSP088189 A EC SP088189A
Authority
EC
Ecuador
Prior art keywords
optionally substituted
aryl
alkyl
heteroaryl group
cycloalkyl
Prior art date
Application number
EC2008008189A
Other languages
English (en)
Inventor
Robert Emmett Mcdevitt
Ronald Charles Bernotas
Hassan Mahmoud Elokdah
Albert Jean Robichaud
Alexander Alexei Greenfield
Kevin Liu
Geraldine Ruth Mcfarlane
Cristina Grosanu
Jennifer Rebecca Lo
Yanfang Li
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088189A publication Critical patent/ECSP088189A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención suministra un compuesto 3-sulfonilindazol de fórmula Ien dondeX es O, S, NR, CH2, CH2Y, CH2Z, CO, CONR o NRCO;Y es O, S o NR;Z es CO;n es 0 o un entero de 1, 2, 3, 4, 5 o 6 cuando X es CH2; n es un entero de 1, 2, 3, 4, 5 o 6 cuando X es CH2Z, CO o NRCO;n es un entero de 2, 3, 4, 5 o 6 cuando X es O, S, NR, CH2Y o CONR;R es H o un grupo alquilo opcionalmente sustituido;R1 es H o un grupo alquilo, cicloalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;R2 es un grupo alquilo, cicloalquilo, arilo o heteroarilo opcionalmente sustituidos un sistema de anillo bicíclico o tricíclico de 8- a 13- miembros opcionalmente sustituido que tiene un átomo N en el cabezal del puente y opcionalmente contiene 1, 2 o 3 heteroátomos seleccionados entre N, O o S;R3 y R4 son cada uno independientemente H, o un grupo alquilo opcionalmente sustituido;R5 y R6 son cada uno independientemente H, o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido, o R5 y R6 pueden ser tomados juntos con el átomo al cual ellos están ligados para formar un anillo de 3- a 7- miembros opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional seleccionado entre O, N o S;R7 es H, halógeno, CN, OR8, CO2R9, CONR10R11, o un grupo alquilo, alquenilo, alquinilo, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo cada uno opcionalmente sustituido;m es un entero de 1, 2 o 3;R8 es H, COR12 o un grupo alquilo, alquenilo, alquinilo, arilo o heteroarilo cada uno opcionalmente sustituido;R9 es H o un alquilo C1-C6, o un grupo arilo o heteroarilo cada uno opcionalmente sustituido;R10 y R11 son cada uno independientemente H o un grupo alquilo opcionalmente sustituido; yR12 es un grupo alquilo C1-C6, cicloalquilo, cicloheteroalquilo, arilo o heteroarilo; oun estereoisómero del mismo o una sal farmacéuticamente aceptable del mismo. La presente invención también suministra métodos y composiciones útiles para el tratamiento terapéutico de trastornos del sistema nervioso central relacionados con o afectados por el receptor 5-HT6.
EC2008008189A 2005-08-15 2008-02-15 Derivados de 3-sulfonilindazol sustituido comoligandos de 5-hidroxitriptamina-6 ECSP088189A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70831505P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
ECSP088189A true ECSP088189A (es) 2008-04-28

Family

ID=37668440

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008189A ECSP088189A (es) 2005-08-15 2008-02-15 Derivados de 3-sulfonilindazol sustituido comoligandos de 5-hidroxitriptamina-6

Country Status (21)

Country Link
US (1) US7723329B2 (es)
EP (1) EP1931640A2 (es)
JP (1) JP5146766B2 (es)
KR (1) KR20080039994A (es)
CN (1) CN101282938A (es)
AR (1) AR057756A1 (es)
AU (1) AU2006280091A1 (es)
BR (1) BRPI0614343A2 (es)
CA (1) CA2619010C (es)
CR (1) CR9734A (es)
EC (1) ECSP088189A (es)
GT (1) GT200600376A (es)
IL (1) IL189476A0 (es)
NO (1) NO20080937L (es)
NZ (1) NZ565872A (es)
PE (1) PE20070354A1 (es)
RU (1) RU2429231C2 (es)
SA (1) SA06270314B1 (es)
TW (1) TW200740766A (es)
UA (1) UA94053C2 (es)
WO (1) WO2007021711A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973876A2 (en) * 2006-01-13 2008-10-01 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
WO2007120599A2 (en) * 2006-04-12 2007-10-25 Wyeth Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
CN101421280A (zh) * 2006-04-12 2009-04-29 惠氏公司 作为5-羟色胺-6配体的经取代二氢[1,4]噁嗪并[2.3.4-hi]吲唑衍生物
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
CN103102348B (zh) * 2011-11-14 2016-06-08 上海交通大学 噁二唑类化合物及其制备方法、药物组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
EP1196380A2 (en) * 1999-07-15 2002-04-17 NPS Allelix Corp. Indoles and indazoles for the treatment of migraine
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1355900B1 (en) * 2000-12-22 2006-05-24 Wyeth Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
CA2432654A1 (en) * 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CN1293072C (zh) * 2001-04-20 2007-01-03 惠氏公司 作为5－羟色胺－6配体的杂环基氧基－、－硫代－和－氨基吲哚衍生物
BR0209047A (pt) * 2001-04-20 2004-08-10 Wyeth Corp Derivados de heterociclilalcóxi-, -alquiltio- e -alquilaminobenzazol como ligantes de 5-hidroxitriptamina-6
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
TW200403243A (en) * 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE60309498T2 (de) * 2002-10-18 2007-08-30 F. Hoffmann-La Roche Ag 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
DE60316180T2 (de) * 2002-12-03 2008-05-29 F. Hoffmann-La Roche Ag Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
RU2347780C2 (ru) * 2003-02-14 2009-02-27 Уайт Гетероциклил-3-сульфонилиндазолы в качестве лигандов 5-гидрокситриптамина-6
EP1592690A1 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20060114022A (ko) * 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
KR20080034497A (ko) * 2005-08-15 2008-04-21 와이어쓰 5-히드록시트립타민-6 리간드로서의 아지닐-3-설포닐인다졸유도체

Also Published As

Publication number Publication date
GT200600376A (es) 2007-03-29
CA2619010C (en) 2013-10-01
US20070037802A1 (en) 2007-02-15
PE20070354A1 (es) 2007-04-04
EP1931640A2 (en) 2008-06-18
UA94053C2 (ru) 2011-04-11
JP2009504739A (ja) 2009-02-05
KR20080039994A (ko) 2008-05-07
NZ565872A (en) 2011-06-30
TW200740766A (en) 2007-11-01
CR9734A (es) 2008-04-03
AU2006280091A1 (en) 2007-02-22
RU2429231C2 (ru) 2011-09-20
JP5146766B2 (ja) 2013-02-20
IL189476A0 (en) 2008-08-07
CN101282938A (zh) 2008-10-08
CA2619010A1 (en) 2007-02-22
SA06270314B1 (ar) 2011-07-20
US7723329B2 (en) 2010-05-25
BRPI0614343A2 (pt) 2011-03-22
WO2007021711A3 (en) 2007-05-03
AR057756A1 (es) 2007-12-19
RU2008105807A (ru) 2009-09-27
NO20080937L (no) 2008-04-30
WO2007021711A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ECSP088189A (es) Derivados de 3-sulfonilindazol sustituido comoligandos de 5-hidroxitriptamina-6
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
BRPI0509390A (pt) derivados de 1-(1h-indol-1-il)-3-(4-metilpiperazin-1-il)-fenil propan-2-ol e compostos relacionados como moduladores da atividade da norepinefrina (ne) e da serotonina (5-th) e da reabsorção da monoamina para o tratamento de sintomas vasomotores (vms)
RU2019143759A (ru) Новое соединение бифенила или его соль
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR110443A1 (es) Inhibidores de histona metiltransferasas
GB0507680D0 (en) Compounds
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
TW200612936A (en) Indole derivatives
AR048523A1 (es) Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
AR066459A1 (es) Derivados de oxadiazol como moduladores de gamma-secretasa. composiciones farmaceuticas
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
EA201001178A1 (ru) 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
ATE484502T1 (de) Neue verbindungen
GB0507601D0 (en) Compounds
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
AR068521A1 (es) Derivados heterociclicos triciclicos